|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 325 7TH STREET, NW, #1200 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31326-12
|
||||||||
|
6. House ID# 313540000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anthony J. Principi |
Date | 04/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
US- China Trade Dialogues (JCCT) - market access and IP issues
Trans Pacific Partnership talks
US - EU Dialogues (TEC) - market access and regulatory issues
Japan Market Access and Regulatory Issues
US-Korea Free Trade Agreement (no bills)
US-Peru Free Trade Agreement (no bills)
US-Columbia Free Trade Agreement (no bills)
US-Panama Free Trade Agreement (no bills)
Poland market access (no bills)
Russia market access (no bills)
Turkey Market Access (no bills)
Israel Patent Issues (no bills)
Taiwan - Market Access Issues (TIFA talks)
APEC Life Sciences Innovation Forum
Mexico IP and market access issues
Brazil IP
Thailand Compulsory Licensing
India IP and market access issues
Australian FTA Implementation
Special 301 Reform Legislation
Trade Enforcement Legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), State - Dept of (DOS), Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joseph |
Damond |
|
|
|
Anthony |
Principi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Veterans Healthcare issues
Health Reform
Comparative Effectiveness Research
Health Information Technology
Follow on Biologics
Medicare Part D
S. 4 - Comprehensive Health Reform Act (1/09)
S. 45 - Health Liability Reduction Act (1/09)
S. 301 - Physician Payments Sunshine Act (1/09)
S. 501 - Fair Prescription Drug Competition Act (3/09)
S. Con Res 13 - Budget Reconciliation
H.R. 15 - National Health Insurance Act (1/09)
H.R. 1 - The American Recovery and Reinvestment Act
H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 2 - Children's Health Insurance Program Reauthorization Act of 2009
H.R. 1548 - Pathway for Biosimilars Act
H.R. 1549 The Preservation of Antibiotics for Medical Treatment Act
H.R. 2400 - Strategies to Address Antimicrobial Resistance Act
H.R. 3200 - America's Affordable Health Choice Act
H.R. 3962 - Affordable Healthcare for America Act
H.R. 3590 - Patient Protection and Affordable Care Act
H.R. 4489 - FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act
H. Con Res 85 - Budget Resolution 2010
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Carey |
|
|
|
Anthony |
Principi |
|
|
|
Bronwen |
Kaye |
|
|
|
Louis A. |
LaMarca |
|
|
|
John |
Halliwell |
|
|
|
Angela |
Riemer |
|
|
|
Maria |
Cino |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Administration budget proposal, deferral and other international tax issues
H.R.3293 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anthony J. |
Principi |
|
|
|
Kimberly |
Pinter |
|
|
|
Bronwen |
Kaye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 515 - Patent Reform Act of 2009
S. 299 - Expert Patent Courts Pilot Program Act, 1/09
S. 369 - Preserve Access to Affordable Generics, 2/09
H.R. 1260 - Patent Reform Act, 3/09
H.R. 1706 - Protecting Consumer Access to Generics Drug Act, 3/09
H.R. 1548 - Pathway for Biosimilars Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Halliwell |
|
|
|
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
S.80 - Pharmaceutical Market Access Act, 1/09
S. 501 - Fair prescription Drug Competition Act, 3/09
S. 882 - Drug and Device Accountability Act
H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09
H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09
H.R. 1548 - Pathway for Biosimilars Act, 3/09
H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09
H.R. 1259 - Dextromethorphan Distribution Act 4/09
S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Halliwell |
|
|
|
Anthony J. |
Principi |
|
|
|
Louis A. |
LaMarca |
|
|
|
Angela |
Riemer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Prescription Drug Benefit Implementation
Medicaid Rebates
Medicare Coverage
Average Manufacturer Price Regulation
H.R. 2502 - Comparative Effectiveness Research Act
H.R. 3200 - America's Affordable Heath Choices Act of 2009.
H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009
H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Chris |
Carey |
|
|
|
John |
Halliwell |
|
|
|
Anthony J. |
Principi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
VA Drug Coverage
Smoking Cessation Coverage
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lou |
LaMarca |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Deferral
Deferral for active-financing income- extension
S. 1203 - R& E Tax Credit Extension and Enhancement
H.R. 422 - R&E Tax Credit Extension and Enhancement
H.R. 2098 - CFC Look Through Extension
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Pinter |
|
|
|
Anthony J. |
Principi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |